# The Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Evaluating Disease Burden in Non-Cystic Fibrosis Bronchiectasis

**Authors:** Ahmet Yurttaş, Deniz Çelik, Sertan Bulut, Özkan Yetkin, Hüseyin Lakadamyalı

PMC · DOI: 10.3390/life16020206 · 2026-01-27

## TL;DR

This study shows that analyzing cells in bronchoalveolar lavage fluid can predict hospitalization risk in bronchiectasis patients.

## Contribution

The study identifies a specific BAL cell profile linked to hospitalization, offering a potential prognostic biomarker for bronchiectasis.

## Key findings

- Hospitalized patients had significantly lower alveolar macrophages and higher eosinophils in BAL.
- BAL cell profiles correlate with clinical outcomes beyond microbiological data.
- A low macrophage/high eosinophil profile may indicate a high-risk bronchiectasis phenotype.

## Abstract

Objective: This study aimed to investigate the relationship between bronchoalveolar lavage (BAL) cellular profiles, microbiological status, and clinical outcomes such as hospital admission in adult patients with non-cystic fibrosis bronchiectasis. Methods: A retrospective cross-sectional study was conducted on thirty adult bronchiectasis patients. Demographic, clinical, and laboratory data were collected. The cellular components of BAL fluid (macrophages, neutrophils, lymphocytes, and eosinophils) were analyzed. Patients were grouped according to the presence of microbial culture growth and history of hospitalization in the past year. Statistical analyses were performed to determine significant relationships. Results: The median age was 57 years, and the gender distribution was equal. There was no significant difference in BAL cellular profiles between groups with and without culture growth. However, in the group with a hospital admission in the past year, BAL showed a significantly lower percentage of alveolar macrophages (20% vs. 47%, p = 0.011) and a higher percentage of eosinophils (5% vs. 1%, p = 0.036). The hospitalized group also showed a trend toward a higher neutrophil percentage and a lower lymphocyte/neutrophil ratio. Furthermore, surprising associations were noted, such as a higher BAL macrophage count in married individuals and higher BAL eosinophilia in patients with diabetes. Conclusions: BAL cellular analysis provides valuable information beyond routine microbiological investigations in bronchiectasis. The low-alveolar-macrophage and high-eosinophil profile was found to be significantly associated with hospitalization, and this profile has the potential to serve as a prognostic biomarker in defining the “high-risk” phenotype. These findings highlight the complexity of the local inflammatory response and reveal the potential role of BAL in developing personalized treatment strategies for patients with bronchiectasis.

## Linked entities

- **Diseases:** bronchiectasis (MONDO:0004822)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** impaired consciousness (MESH:D003244), hypertension (MESH:D006973), immunodeficiency syndromes (MESH:D007153), Bronchiectasis (MESH:D001987), bacterial colonization (MESH:D015179), cough (MESH:D003371), weight loss (MESH:D015431), IPF (MESH:D054990), infection (MESH:D007239), dilation of the bronchi (MESH:D002311), acute and chronic airway infection (MESH:D054198), dementia (MESH:D003704), tuberculosis (MESH:D014376), mucociliary dysfunction (MESH:D006331), ciliary dysfunction (MESH:D002925), crackles (MESH:D012135), heart failure (MESH:D006333), fungal (MESH:D009181), bronchial dilatation (MESH:D001982), respiratory diseases (MESH:D012140), coronary syndrome (MESH:D054058), Parkinson's disease (MESH:D010300), injury to (MESH:D014947), airway inflammation (MESH:D007249), Fibrosis (MESH:D005355), CF (MESH:D003550), asthma (MESH:D001249), decline in lung function (MESH:D055370), Alzheimer's disease (MESH:D000544), Dyspnea (MESH:D004417), lung (MESH:D008171), diabetes (MESH:D003920), cancer (MESH:D009369), chest infections (MESH:D002637), clubbing (MESH:D003025), COPD (MESH:D029424), hemoptysis (MESH:D006469), hypoxemia (MESH:D000860), airway obstruction (MESH:D000402)
- **Chemicals:** Lowenstein-Jensen medium (-), urea (MESH:D014508), macrolide (MESH:D018942), creatinine (MESH:D003404), reactive oxygen species (MESH:D017382), clarithromycin (MESH:D017291)
- **Species:** Stenotrophomonas maltophilia (species) [taxon 40324], Haemophilus influenzae (species) [taxon 727], Homo sapiens (human, species) [taxon 9606], Enterobacteriaceae (enterobacteria, family) [taxon 543], Escherichia coli (E. coli, species) [taxon 562], Pseudomonas aeruginosa (species) [taxon 287], Streptococcus pneumoniae (species) [taxon 1313]

---
Source: https://tomesphere.com/paper/PMC12942116